Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Alliance Global Partners initiated coverage on Akari Therapeutics in a research note on Tuesday, November 1st. They issued a “buy” rating and a $4.00 price target for the company. HC Wainwright initiated coverage on Akari Therapeutics in a report on Monday, December 5th. They issued a “buy” rating and a $1.50 target price for the company.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX opened at $0.54 on Monday. The stock has a market cap of $40.17 million, a price-to-earnings ratio of -1.54 and a beta of 1.32. The business has a 50 day simple moving average of $0.52 and a 200 day simple moving average of $0.76. Akari Therapeutics has a 52 week low of $0.38 and a 52 week high of $1.61.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. LPL Financial LLC bought a new stake in Akari Therapeutics in the second quarter valued at $83,000. Omnia Family Wealth LLC lifted its stake in shares of Akari Therapeutics by 3.2% during the third quarter. Omnia Family Wealth LLC now owns 782,372 shares of the biopharmaceutical company’s stock valued at $493,000 after acquiring an additional 24,228 shares during the period. Finally, Armistice Capital LLC acquired a new position in shares of Akari Therapeutics during the third quarter valued at $2,703,000. 13.59% of the stock is currently owned by institutional investors and hedge funds.

Akari Therapeutics Company Profile

(Get Rating)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.